What does an endotoxin test add for a GLP-1 receptor agonist that a purity figure does not?

What I am working with: an endotoxin test · a GLP-1 receptor agonist.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

Is there a defensible reason to prefer one, or is this a coin flip?

On the detail: the honest answer is that you cannot know for certain what you have without a content assay, and the purity number alone is not enough.

System suitability for a quantitative method is stricter than for purity because a small systematic error in the standard directly translates into an error in the sample result.

The purity of the reference standard is stated on its certificate, and your content figure is only as good as that purity certificate is.

The relative standard deviation on replicate quantitations of a homogeneous sample should be below two per cent when the method is under control.

If a supplier gives you content without the standard's purity, ask them to provide it.

It helps to be literal here: start from what you are trying to know — whether a vial contains what the label claims — and purity does not answer that question.

For peptides at 214 nanometres the response is roughly proportional to the number of peptide bonds, so truncation impurities have lower response factors and overestimate content.

Peak area for a standard of known weight produces a response factor — area per unit mass — which is then applied to the sample peak to infer sample mass.

Where content data have been published from testing services on common peptides, the spread between services on identical material is typically a few per cent.

One qualification: a single result from a single vial is a point estimate, and repeating the assay on a second aliquot is worth doing if the first result is surprising.

The practical summary: if you are ordering from a new supplier, budget for content assay on the first lot.

The short answer is that purity says "what fraction of detected material is the target" while content says "how many milligrams of the target are present," and those are two different things.

If a sample shows high purity but low content, the explanation is usually that the standard used for quantitation had a different purity than claimed.

Concretely, quantitation against a certified reference material assumes the sample and standard are treated identically through the analytical method, which is why the method for calibration matters as much as the method for measurement.

The caveat is that content assay costs more than purity, so most people do not do it, which is exactly why it is valuable on the first lot from a new supplier.

Ask for both the purity and the content, and do not accept purity alone.

edited 29 Jul 2026 by Dr_Jonas_Halvorsen — added the method parameters

Most research-grade certificates report purity without content, which is exactly backwards from what users actually need.

The single most common reason for disagreement between a supplier content figure and an independent assay is using different standards.

Pharmacopoeial guidance on quantitative methods specifies validation steps for linearity, range, accuracy and precision that most research-grade work does not claim to meet.

The limitation is that a quantitative method is only as good as the standard it uses, and a cheap standard is a false economy.

If a supplier gives you content without the standard's purity, ask them to provide it.

edited 31 Jul 2026 by e_dziedzic — reworded for clarity after a comment